91
92
93
94
95
96
97
98
Morales, Daniel R., Morant, Steve V., MacDonald, Thomas M., Mackenzie, Isla S., Doney, Alexander S. F., Mitchell, Lyn, Bennie, Marion, Robertson, Chris, Hallas, Jesper, Pottegard, Anton, Ernst, Martin Thomsen, Wei, Li, Nicholson, Lizzie, Morris, Carole, Herings, Ron M. C., Overbeek, Jetty A., Smits, Elisabeth, Flynn, Robert W. V.
Veröffentlicht in: Morales , D R , Morant , S V , MacDonald , T M , Mackenzie , I S , Doney , A S F , Mitchell , L , Bennie , M , Robertson , C , Hallas , J , Pottegard , A , Ernst , M T , Wei , L , Nicholson , L , Morris , C , Herings , R M C , Overbeek , J A , Smits , E & Flynn , R W V 2020 , ' Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands ' , Pharmacoepidemiology and Drug Safety , vol. 29 , no. 3 , pp. 296-305 . https://doi.org/10.1002/pds.4955;
2020
Veröffentlicht in: Morales , D R , Morant , S V , MacDonald , T M , Mackenzie , I S , Doney , A S F , Mitchell , L , Bennie , M , Robertson , C , Hallas , J , Pottegard , A , Ernst , M T , Wei , L , Nicholson , L , Morris , C , Herings , R M C , Overbeek , J A , Smits , E & Flynn , R W V 2020 , ' Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands ' , Pharmacoepidemiology and Drug Safety , vol. 29 , no. 3 , pp. 296-305 . https://doi.org/10.1002/pds.4955;
2020
99
Morales, Daniel R., Macfarlane, Tatiana, MacDonald, Thomas M., Hallas, Jesper, Ernst, Martin Thomsen, Herings, Ron M. C., Smits, Elisabeth, Overbeek, Jetty A., Mitchell, Lyn, Morant, Steven, Mackenzie, Isla, Doney, Alexander, Robertson, Chris, Bennie, Marion, Wei, Li, Nicholson, Lizzie, Morris, Carole, Flynn, Robert W. F.
Veröffentlicht in: Morales , D R , Macfarlane , T , MacDonald , T M , Hallas , J , Ernst , M T , Herings , R M C , Smits , E , Overbeek , J A , Mitchell , L , Morant , S , Mackenzie , I , Doney , A , Robertson , C , Bennie , M , Wei , L , Nicholson , L , Morris , C & Flynn , R W F 2021 , ' Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands : an interrupted time series regression analysis ' , Pharmacoepidemiology and Drug Safety , vol. 30 , no. 4 , pp. 482-491 . https://doi.org/10.1002/pds.5191;
2021
Veröffentlicht in: Morales , D R , Macfarlane , T , MacDonald , T M , Hallas , J , Ernst , M T , Herings , R M C , Smits , E , Overbeek , J A , Mitchell , L , Morant , S , Mackenzie , I , Doney , A , Robertson , C , Bennie , M , Wei , L , Nicholson , L , Morris , C & Flynn , R W F 2021 , ' Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands : an interrupted time series regression analysis ' , Pharmacoepidemiology and Drug Safety , vol. 30 , no. 4 , pp. 482-491 . https://doi.org/10.1002/pds.5191;
2021
100